title: Targeted gene therapy for cancer: herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells.
authors.affiliation: Imperial Cancer Research Fund Laboratory of Cancer Gene Therapy, Hammersmith Hospital, London, U.K.
authors.forename: R G
authors.initials: RG
authors.lastname: Vile
authors.forename: R M
authors.initials: RM
authors.lastname: Diaz
authors.forename: S
authors.initials: S
authors.lastname: Castleden
authors.forename: H
authors.initials: H
authors.lastname: Chong
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D016207:Cytokines / Q000096:biosynthesis*; D015774:Ganciclovir / Q000627:therapeutic use; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007249:Inflammation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D018139:Simplexvirus / Q000201:enzymology / Q000235:genetics*; D013601:T-Lymphocytes / Q000276:immunology; D013937:Thymidine Kinase / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D000998:Antiviral Agents; D016207:Cytokines; D013937:Thymidine Kinase; D015774:Ganciclovir